Health Care·Biotechnology·$28.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.52 | N/A | -41.30% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.52 | N/A | -41.30% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding the company's financial outlook. They highlighted ongoing challenges but did not provide specific guidance.
Management did not provide specific revenue figures or guidance for future quarters.
The company acknowledged challenges in the current market environment.
The earnings report indicates that Revolution Medicines is facing challenges, as reflected in their missed EPS target. The stock reacted negatively, dropping 3.33%, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's future performance without clear direction from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AXSOME THERAPEUTICS
Mar 1, 2021